KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Hims & Hers Health (HIMS) EBITDA (2019 - 2026)

Hims & Hers Health's EBITDA history spans 8 years, with the latest figure at -$98.8 million for Q1 2026.

  • On a quarterly basis, EBITDA fell 299.04% to -$98.8 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$17.5 million, a 110.63% decrease, with the full-year FY2025 number at $131.0 million, up 4.09% from a year prior.
  • EBITDA hit -$98.8 million in Q1 2026 for Hims & Hers Health, down from $22.0 million in the prior quarter.
  • Over the last five years, EBITDA for HIMS hit a ceiling of $76.0 million in Q3 2024 and a floor of -$98.8 million in Q1 2026.
  • Historically, EBITDA has averaged $4.0 million across 5 years, with a median of $1.3 million in 2023.
  • Biggest five-year swings in EBITDA: soared 1931.26% in 2024 and later plummeted 299.04% in 2026.
  • Tracing HIMS's EBITDA over 5 years: stood at -$10.7 million in 2022, then surged by 111.7% to $1.3 million in 2023, then soared by 1931.26% to $25.5 million in 2024, then fell by 13.73% to $22.0 million in 2025, then tumbled by 549.69% to -$98.8 million in 2026.
  • Business Quant data shows EBITDA for HIMS at -$98.8 million in Q1 2026, $22.0 million in Q4 2025, and $15.9 million in Q3 2025.